Business Wire - Dyloject™ Significantly Reduces Moderate-to-Severe Pain in Pivotal Phase 3 Orthopedic Surgical Trial
Monday, January 5th, 2009 Trial Successful, Javelin Pharmaceuticals on Track to Submit New Drug Application to US FDA in 2009
CAMBRIDGE, Mass. — Javelin Pharmaceuticals (AMEX: JAV) announced today that its US product candidate Dyloject(TM) (diclofenac sodium for injection) met primary efficacy endpoints with rob…
